Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights

Detailed price information for Tvardi Therapeutics Inc (TVRD-Q) from The Globe and Mail including charting and trades.
The American Journal of Managed Care

Noninvasive Test Shows Accuracy for Detecting Advanced Liver Fibrosis in MASH

The BMP8A Fibrosis Score (BFS) offers improved accuracy over existing noninvasive scoring systems for identifying advanced liver fibrosis in MASH patients. BFS eliminates grey-zone results, providing ...
The American Journal of Managed Care

Noninvasive Tests Show Promise for Tracking Treatment Response in Semaglutide MASH Trial

Blood-based biomarkers and imaging measures may help monitor MASH disease activity, potentially reducing reliance on liver biopsies. Semaglutide treatment showed significant improvements in liver ...

Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio

Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt ...